Lunai Bioworks Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lunai Bioworks Inc. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Lunai Bioworks Inc. stock issued during period, value, new issues for the quarter ending 2022-03-31 was $451.70K.
- Lunai Bioworks Inc. stock issued during period, value, new issues for the quarter ending 2018-12-31 was $11.11M.
- Lunai Bioworks Inc. stock issued during period, value, new issues for the quarter ending 2018-09-30 was $40.00K.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-12 | |
| 2022-03-31 | $451.70K 10-Q · filed 2022-05-13 | |
| 2018-12-31 | $11.11M 10-Q · filed 2019-05-16 | |
| 2018-09-30 | $40.00K 10-Q · filed 2020-05-11 | |
| 2015-03-31 | $12.00M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | -$2.45M derived: 10-Q 12 month − 10-Q 9 month · filed 2015-05-13 | $2.00M 10-Q · filed 2015-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |